Merck KGaA of Germany announced China approval of Erbitux® to treat patients with head and neck cancer. Last year, Erbitux was granted its first approval by China's NMPA for RAS wild-type metastatic colorectal cancer. The new indication of the EFGR drug is for first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) in combination with platinum-based therapy. In 1998, Merck acquired global marketing rights to Erbitux from Lilly outside of the US and Canada. More details...
Stock Symbol: (DE: MRK) (NYSE: LLY)
Share this with colleagues:
Original Article: Merck Announces China Erbitux Approval for Head and Neck Cancer